CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the ...

31 июл. 2024 г. · For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, ...

CARVYKTI ® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at ...

CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product, containing T cells transduced ex vivo using a replication ...

CARVYKTI is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.

CARVYKTI is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with ...

CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma.

CARVYKTI is an engineered T cell product derived from a patient's blood. To ensure the engineered T cells are not filtered out during infusion, while ...

FDA-Approved Indication Carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines ...

28 февр. 2022 г. · Diagnosis of relapsed or refractory MM;. 2. Prescribed by or in consultation with an oncologist or hematologist;. 3. Age ≥ 18 years;.